Colorado is currently home to 1784 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Denver, Aurora, Colorado Springs and Englewood. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
NCT05511922
Recruiting
This is a multicenter pharmacokinetic (PK) subtrial to investigate the PK profile of KVD900 (sebetralstat) in adolescent patients 12 to 17 years of age with Hereditary Angioedema (HAE) type I or II.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
01/06/2025
Locations: KalVista Investigative Site, Centennial, Colorado
Conditions: Hereditary Angioedema
Register for Updates
Hearing Impairment, Strategies and Outcomes in VA Emergency Departments
NCT05028972
Recruiting
HearVA involves six VA facility emergency departments (ED) over a 3-year intervention period. The first part of this study will test whether providing personal amplifiers to Veteran ED patients who self-report hearing difficulty is acceptable to these patients, can improve their hearing, enhance understanding of discharge instructions, and can reduce the risk of coming back to the ED in a short period of time (3 days and 30 days). The second part of the study will then identify whether ED staff... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
01/06/2025
Locations: Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora, Colorado
Conditions: Hearing Loss, Emergency Service, Hospital Readmission
Register for Updates
Autus Valve Pivotal Study
NCT05006404
Recruiting
Prospective, single-arm, multi-center study to evaluate safety and effectiveness of the Autus Size-Adjustable Valve in pediatric patients aged 18 months to 16 years requiring surgical pulmonary valve replacement. The Autus Valve may be expanded pre-implant to match the subject's body size. Subjects will be evaluated prior to the Autus Valve implant procedure, immediately post-implant, at hospital discharge, 30 days, 6 months, and annually through 10 years. The Autus Valve may be expanded post-i... Read More
Gender:
ALL
Ages:
Between 18 months and 16 years
Trial Updated:
01/06/2025
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: Congenital Heart Disease
Register for Updates
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors
NCT06566079
Recruiting
This is a Phase 1, open-label, multicenter, FIH study to evaluate the safety, tolerability, recommended Phase 2 dose (RP2D), PK/PD, and preliminary anti-tumor activity of ISM6331 in participants with advanced or metastatic malignant mesothelioma or other solid tumors. The study consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/03/2025
Locations: Sarah Cannon Research Institute at HealthONE, Denver, Colorado
Conditions: Malignant Mesothelioma, Metastatic Malignant Solid Tumor, Advanced Solid Tumor
Register for Updates
Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors
NCT06414460
Recruiting
The study has consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2). The primary objectives of this study are to evaluate the safety and tolerability of ISM3412 in participants with locally advanced/metastatic solid tumors, and to determine the RP2D of ISM3412.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/03/2025
Locations: Sarah Cannon Research Institute at HealthONE, Denver, Colorado
Conditions: Locally Advanced/Metastatic Solid Tumors
Register for Updates
CtDNA Based MRD Testing for NAC Monitoring in TNBC
NCT06230185
Recruiting
A prospective, multicenter, observational study to evaluate the correlation of Molecular Residual Disease (MRD) detection using circulating tumor DNA guided test to pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in stage I-III triple negative breast cancer (TNBC). Results from this study aim to improve MRD detection and disease outcomes for future patients.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/03/2025
Locations: University of Colorado Cancer Center, Aurora, Colorado
Conditions: TNBC - Triple-Negative Breast Cancer, Minimal Residual Disease
Register for Updates
ProSPective Evaluation of Non-contrast sINe spiN Flat-dEtectoR CT for the Detection of Intracranial hemorrhageS
NCT05458908
Recruiting
Stroke is one of the leading causes of mortality and disability worldwide. Optimization of intra-hospital pathways is as of today one of the most promising research topics in stroke treatment. A potential solution to shorten the time needed for current workflows, and therefore reperfusion, is to do both imaging and subsequent endovascular therapy (EVT) in the angiography suite using non-contrast syngo DynaCT Sine Spin (FDCT) for the exclusion of intracranial hemorrhage and flat detector CT angio... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/03/2025
Locations: Swedish Medical Center, Denver, Colorado
Conditions: Stroke
Register for Updates
Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
NCT06429449
Recruiting
This is an open label, phase 1 study for AML subjects with relapsed or refractory disease or subjects in morphologic remission with MRD+ after first line therapy with venetoclax+HMA. A preliminary dose-finding cohort will be followed by 3 expansion cohorts.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/02/2025
Locations: University of Colorado Hospital, Aurora, Colorado
Conditions: Leukemia, Myeloid Leukemia, Monocytic Leukemia
Register for Updates
Cladribine Venetoclax in Monocytic AML
NCT06232655
Recruiting
Investigation of Relapsed or refractory AML with a monocytic phenotype after failure of hypomethylating agent+venetoclax
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
01/02/2025
Locations: Universtiy of Colorado Hospital, Aurora, Colorado
Conditions: Acute Myeloid Leukemia
Register for Updates
The Society for Obstetric Anesthesia and Perinatology Research Network General Anesthesia Registry
NCT06030063
Recruiting
The SOAP registry is a prospective, multicenter, electronic registry. The goal is to investigate the indications, mode of airway management, predisposing factors, and obstetric and anesthetic outcomes of pregnant patients who receive general anesthesia for cesarean delivery.
Gender:
FEMALE
Ages:
Between 15 years and 55 years
Trial Updated:
01/02/2025
Locations: University of Colorado Hospital, Arvada, Colorado
Conditions: Cesarean Delivery, General Anesthesia
Register for Updates
CC-486 and Venetoclax for Acute Myeloid Leukemia
NCT05287568
Recruiting
This is an open label, dose escalation Phase I single institution pilot study for relapsed and refractory AML patients using CC-486 (oral azacitidine) with venetoclax. At the completion of dose escalation and after establishment of the MTD or recommended dose of CC-486 with venetoclax, an expansion phase will commence, using venetoclax with the MTD of CC-486 in relapsed/refractory patients.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
01/02/2025
Locations: CU Anschutz Medical Campus, Aurora, Colorado
Conditions: AML
Register for Updates
A Study of NX-1607 in Adults With Advanced Malignancies
NCT05107674
Recruiting
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/02/2025
Locations: University of Colorado School of Medicine, Aurora, Colorado
Conditions: Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer (NSCLC), Metastatic Castration-resistant Prostate Cancer (mCRPC), Malignant Pleural Mesothelioma (MPM), Triple Negative Breast Cancer (TNBC), Metastatic Urothelial Carcinoma, Cervical Cancer, Metastatic or Unresectable Melanoma, Diffuse Large B Cell Lymphoma (DLBCL), Richter Transformation, Microsatellite Stable Colorectal Carcinoma
Register for Updates